-+ 0.00%
-+ 0.00%
-+ 0.00%

Mizuho Maintains Outperform on Medline, Lowers Price Target to $45

Benzinga·10/22/2026 11:54:18
Listen to the news
Mizuho analyst Steven Valiquette maintains Medline (NASDAQ:MDLN) with a Outperform and lowers the price target from $48 to $45.